Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/22/2025

Edema Management with Loop Diuretics

Initial Therapy and Diuretic Selection

  • The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend starting with furosemide as first-line therapy for edema management, with torsemide reserved for cases where there are concerns about treatment failure or oral bioavailability 1
  • The American College of Cardiology (ACC) and American Heart Association (AHA) heart failure guidelines state that furosemide is the most commonly used loop diuretic for the treatment of heart failure 2
  • For patients with severe heart failure or cirrhosis, torsemide may be preferred due to its more consistent bioavailability 3

Dosing Considerations and Switching Diuretics

  • When switching from furosemide to torsemide, approximately half the furosemide dose should be used (10-20mg torsemide ≈ 20-40mg furosemide) 1
  • Furosemide should be started with low doses (20-40mg) and titrated based on response 1

Special Considerations and Combination Therapy

  • In patients with severe heart failure or cirrhosis, torsemide may be considered due to its more consistent bioavailability 3
  • For patients requiring hospitalization for acute heart failure, IV furosemide remains the standard initial therapy, with consideration of torsemide if response is inadequate 4
  • When using diuretics with albumin (for severe hypoalbuminemia), furosemide has been more extensively studied 5
  • In resistant edema, adding thiazide diuretics or potassium-sparing diuretics may be more effective than simply switching loop diuretics 1, 2

Guideline Recommendations and Clinical Practice

  • The ACC/AHA heart failure guidelines recommend furosemide as the most commonly used loop diuretic for the treatment of heart failure 2
  • The KDIGO guidelines recommend reserving torsemide for cases where there are concerns about treatment failure or oral bioavailability 1